- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Doctors Need to Be Tech Savvy, Report Suggests
The survey, conducted by salesforce.com, showed that 71% patients want their doctor to use a mobile application to schedule appointments, share health data, and manage preventive care; 60% patients reported an interest in using telehealth in place of in-person visits.
Americans with health insurance are for the most part satisfied with their care, but are using antiquated methods to manage their health, and in the future, healthcare providers may feel pressure to use more modern technologies from the next generation of patients.
That’s according to research from salesforce.com. The “2015 State of the Connected Patient Report,” based on interviews with 1,700 adults with health insurance and a primary care physician, found technology is not being used to its full potential. For example, fewer than 10 percent of those surveyed use the web, email or text to set up an appointment. The survey found that just 21 percent of respondents said they use the Web to access their health data.
“This lack of technology could be at least partly responsible for challenges around preventative care in America, as 40 percent of respondents said they receive no ongoing care recommendations from their physician,” the report said.
Link to the complete article:
Source: Government HealthIT
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
